Valneva IPO Presentation Deck

VLA1553 - Only Chikungunya Vaccine Candidate in Phase 3 Today 1 Phase 3 trial VLA1553-301 fully enrolled¹; Use of surrogate marker for Ph3 endpoint confirmed by FDA2; Accelerated Approval Pathway confirmed³ 2 3 Potentially eligible for Priority Review Voucher4; FDA Fast Track5 and EMA PRIME designation granted Single shot, live attenuated prophylactic vaccine targeting chikungunya virus neutralization 4 Up to $23.4 million awarded to Valneva for R&D by CEPI; Partnership with Instituto Butantan for LMICS8 Valneva - Roadshow Presentation 5 Excellent fit with existing commercial and manufacturing capabilities Note: Photo credit: James Gathany. 1 Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and Initiates Antibody Persistence Trial 2 Valneva Announces Publication of 2020 Universal Registration Document and Provides Business Updates 3 Valneva reports positive End-of-Phase 2 Chikungunya meeting with the U.S. FDA and sets stage for Phase 3 Study; 4 https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/tropical-disease-priority-review-voucher-program. 5 Valneva awarded FDA Fast Track Designation for Chikungunya vaccine candidate. 6 Valneva's Chikungunya vaccine candidate awarded EMA prime designation. 7 CHIKV LR2006-OPY1 infectious clone was attenuated by deleting large part of gene coding nsP3 (alphavirus-replicase). 8 Valneva to partner with Instituto Butantan on single-shot Chikungunya vaccine for low- and middle- Income countries. April 2021 18

View entire presentation